Referencia número: HY-16586

PFI-1

4 Cited Publications

Revisión del cliente

Based on 4 publication(s) in Google Scholar

PFI-1, a chemical probe, is a selective BET (bromodomain-containing protein) inhibitor for BRD4 with IC₅₀ of 0.22 μM in a cell-free assay.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.87%
No. CAS: 1403764-72-6
Fòrmula: C₁₆H₁₇N₃O₄S
Peso molecular:347.39

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

PFI-1 Chemical Structure

No. CAS: 1403764-72-6

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

PFI-1, a chemical probe, is a selective BET (bromodomain-containing protein) inhibitor for BRD4 with IC₅₀ of 0.22 μM in a cell-free assay.

IC₅₀ & Target

IC50: 0.22 μM (BRD4)

Ver todos los productos específicos de isoformas Epigenetic Reader Domain :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	GI₅₀	12 μM Compound: 7; PFI-1	Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
A498	GI₅₀	1.8 μM Compound: 7; PFI-1	Growth inhibition of human A498 cells after 48 hrs by SRB assay Growth inhibition of human A498 cells after 48 hrs by SRB assay	[PMID: 29776834]
A549	GI₅₀	19.5 μM Compound: 7; PFI-1	Growth inhibition of human A549/ATCC cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A549/ATCC cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
ACHN	GI₅₀	7.8 μM Compound: 7; PFI-1	Growth inhibition of human ACHN cells after 48 hrs by sulforhodamine B assay Growth inhibition of human ACHN cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
BT-549	GI₅₀	14.8 μM Compound: 7; PFI-1	Growth inhibition of human BT549 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human BT549 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
CAKI-1	GI₅₀	3.6 μM Compound: 7; PFI-1	Growth inhibition of human CAKI-1 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human CAKI-1 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
CCRF-CEM	GI₅₀	7.8 μM Compound: 7; PFI-1	Growth inhibition of human CCRF-CEM cells after 48 hrs by sulforhodamine B assay Growth inhibition of human CCRF-CEM cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
COLO 205	GI₅₀	3 μM Compound: 7; PFI-1	Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
DU-145	GI₅₀	28.8 μM Compound: 7; PFI-1	Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
HCT-116	GI₅₀	4.5 μM Compound: 7; PFI-1	Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
HCT-15	GI₅₀	3.2 μM Compound: 7; PFI-1	Growth inhibition of human HCT15 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HCT15 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
HL-60	IC₅₀	2.19 μM Compound: 1; PFI-1	Cytotoxicity against human HL60 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27266999]
HL-60	IC₅₀	3.99 μM Compound: PFI-1	Antiproliferative activity against human HL60 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HL60 cells incubated for 72 hrs by CCK8 assay	[PMID: 32883643]
HL-60(TB)	GI₅₀	3.4 μM Compound: 7; PFI-1	Growth inhibition of human HL-60(TB) cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HL-60(TB) cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
HOP-62	GI₅₀	2.5 μM Compound: 7; PFI-1	Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
HOP-92	GI₅₀	1.2 μM Compound: 7; PFI-1	Growth inhibition of human HOP92 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HOP92 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
Hs-578T	GI₅₀	1.9 μM Compound: 7; PFI-1	Growth inhibition of human Hs 578T cells after 48 hrs by sulforhodamine B assay Growth inhibition of human Hs 578T cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
HT-29	GI₅₀	3 μM Compound: 7; PFI-1	Growth inhibition of human HT-29 cells after 48 hrs by SRB assay Growth inhibition of human HT-29 cells after 48 hrs by SRB assay	[PMID: 29776834]
HT-29	IC₅₀	14.72 μM Compound: PFI-1	Antiproliferative activity against human HT29 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HT29 cells incubated for 72 hrs by MTT assay	[PMID: 32883643]
IGROV-1	GI₅₀	6.3 μM Compound: 7; PFI-1	Growth inhibition of human IGROV1 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human IGROV1 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
K562	GI₅₀	4.6 μM Compound: 7; PFI-1	Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
KM12	GI₅₀	10.7 μM Compound: 7; PFI-1	Growth inhibition of human KM12 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human KM12 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
LOX IMVI	GI₅₀	3.5 μM Compound: 7; PFI-1	Growth inhibition of human LOXIMVI cells after 48 hrs by sulforhodamine B assay Growth inhibition of human LOXIMVI cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
M14	GI₅₀	2.9 μM Compound: 7; PFI-1	Growth inhibition of human M14 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human M14 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
MCF7	GI₅₀	1.5 μM Compound: 7; PFI-1	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 29776834]
MDA-MB-231	GI₅₀	3.5 μM Compound: 7; PFI-1	Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
MDA-MB-435	GI₅₀	2.6 μM Compound: 7; PFI-1	Growth inhibition of human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
MDA-MB-468	GI₅₀	1.5 μM Compound: 7; PFI-1	Growth inhibition of human MDA-MB-468 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-468 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
MOLT-4	GI₅₀	10.5 μM Compound: 7; PFI-1	Growth inhibition of human MOLT4 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MOLT4 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
MV4-11	IC₅₀	7.75 μM Compound: 1; PFI-1	Cytotoxicity against human MV4-11 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27266999]
NCI/ADR-RES	GI₅₀	17.4 μM Compound: 7; PFI-1	Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
NCI-H226	GI₅₀	14.1 μM Compound: 7; PFI-1	Growth inhibition of human NCI-H226 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H226 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
NCI-H23	GI₅₀	8.5 μM Compound: 7; PFI-1	Growth inhibition of human NCI-H23 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H23 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
NCI-H322M	GI₅₀	6 μM Compound: 7; PFI-1	Growth inhibition of human NCI-H322M cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H322M cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
NCI-H460	GI₅₀	9.3 μM Compound: 7; PFI-1	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
NCI-H522	GI₅₀	8.7 μM Compound: 7; PFI-1	Growth inhibition of human NCI-H522 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H522 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
OVCAR-3	GI₅₀	4 μM Compound: 7; PFI-1	Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
OVCAR-4	GI₅₀	6.3 μM Compound: 7; PFI-1	Growth inhibition of human OVCAR4 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR4 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
OVCAR-5	GI₅₀	10.5 μM Compound: 7; PFI-1	Growth inhibition of human OVCAR5 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR5 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
OVCAR-8	GI₅₀	9.1 μM Compound: 7; PFI-1	Growth inhibition of human OVCAR8 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR8 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
PBMC	EC₅₀	1.89 μM Compound: 17, PFI-1, PF-6405761, 4E96	Inhibition of LPS-induced IL6 production in human PBMC by ELISA Inhibition of LPS-induced IL6 production in human PBMC by ELISA	[PMID: 23095041]
PC-3	GI₅₀	28.2 μM Compound: 7; PFI-1	Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
RPMI-8226	GI₅₀	2.2 μM Compound: 7; PFI-1	Growth inhibition of human RPMI8226 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human RPMI8226 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
RXF 393	GI₅₀	7.9 μM Compound: 7; PFI-1	Growth inhibition of human RXF393 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human RXF393 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SF-268	GI₅₀	28.8 μM Compound: 7; PFI-1	Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SF-295	GI₅₀	13.5 μM Compound: 7; PFI-1	Growth inhibition of human SF295 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SF295 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SF-539	GI₅₀	4.5 μM Compound: 7; PFI-1	Growth inhibition of human SF539 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SF539 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SK-MEL-2	GI₅₀	29.5 μM Compound: 7; PFI-1	Growth inhibition of human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SK-MEL-28	GI₅₀	6.2 μM Compound: 7; PFI-1	Growth inhibition of human SK-MEL-28 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-28 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SK-MEL-5	GI₅₀	6.3 μM Compound: 7; PFI-1	Growth inhibition of human SK-MEL-5 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-5 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SK-OV-3	GI₅₀	4.9 μM Compound: 7; PFI-1	Growth inhibition of human SKOV3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SKOV3 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SN12C	GI₅₀	6.8 μM Compound: 7; PFI-1	Growth inhibition of human SN12C cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SN12C cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SNB-19	GI₅₀	4.8 μM Compound: 7; PFI-1	Growth inhibition of human SNB19 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SNB19 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SNB-75	GI₅₀	0.4 μM Compound: 7; PFI-1	Growth inhibition of human SNB75 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SNB75 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SR	GI₅₀	3.7 μM Compound: 7; PFI-1	Growth inhibition of human SR cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SR cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SW-620	GI₅₀	12 μM Compound: 7; PFI-1	Growth inhibition of human SW620 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SW620 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
T47D	GI₅₀	3.7 μM Compound: 7; PFI-1	Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
THP-1	IC₅₀	0.43 μM Compound: 1; PFI-1	Antiinflammatory activity against human THP-1 cells assessed as inhibition of LPS-induced IL-6 production incubated for 18 hrs by ELISA Antiinflammatory activity against human THP-1 cells assessed as inhibition of LPS-induced IL-6 production incubated for 18 hrs by ELISA	[PMID: 35318165]
TK-10	GI₅₀	1.6 μM Compound: 7; PFI-1	Growth inhibition of human TK10 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human TK10 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
U-251	GI₅₀	15.1 μM Compound: 7; PFI-1	Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
U-937	IC₅₀	>20 μM Compound: 1; PFI-1	Cytotoxicity against human U937 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human U937 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27266999]
UACC-257	GI₅₀	3.6 μM Compound: 7; PFI-1	Growth inhibition of human UACC257 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human UACC257 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
UACC-62	GI₅₀	0.7 μM Compound: 7; PFI-1	Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
UO-31	GI₅₀	1.1 μM Compound: 7; PFI-1	Growth inhibition of human UO31 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human UO31 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
WI-38	IC₅₀	19.8 μM Compound: PFI-1	Antiproliferative activity against human WI-38 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human WI-38 cells incubated for 72 hrs by MTT assay	[PMID: 32883643]

In Vitro

PFI-1 has antiproliferative effects on leukemic cell lines and efficiently abrogates their clonogenic growth. Exposure of sensitive cell lines with PFI-1 results in G1 cell-cycle arrest, downregulation of MYC expression, as well as induction of apoptosis and induces differentiation of primary leukemic blasts. Cells exposed to PFI-1 show significant downregulation of Aurora B kinase, thus attenuating phosphorylation of the Aurora substrate H3S10, providing an alternative strategy for the specific inhibition of this well-established oncology target^[1]. PFI-1 binds to with cyclic AMP response binding protein with K_d of 49 μM. PFI-1 has an EC₅₀ of 1.89 μM for the inhibition of IL6 production from human blood mononuclear cells stimulated by LPS^[2]. PFI-1 induces dose-dependent reduction of cell viability in T4302 CD133⁺ cells^[3]. PFI-1 inhibits the proliferating of three NET cell lines (Bon-1 derived from a pancreatic NET, and H727 and H720 derived from lung NETs)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PFI-1 administrated (1 mg/kg, i.v.) in the rat results in the volume of distribution of 1 L/kg, the plasma clearance of 18 mL/min/kg and half-life of 1 hour. PFI-1 oral dosed (2 mg/kg) in the rat results in the oral bioavailability as low as 32%. PFI-1 administrated (2 mg/kg, s.c.) in the mouse results in a Cmax of 58 ng/mL with a Tmax of 1 h and a half-life of approximately 2 hours^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

No. CAS 1403764-72-6
Appearance Solid
Peso molecular 347.39
Fòrmula C₁₆H₁₇N₃O₄S
Color Light yellow to yellow
SMILES

O=S(C1=CC=CC=C1OC)(NC2=CC3=C(NC(N(C)C3)=O)C=C2)=O
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (4)

All

Sort by:

Journal Impact Factor

Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Proc Natl Acad Sci U S A

MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer. [Abstract]

2019 Feb 19;116(8):2961-2966. PMID: 30718431
bioRxiv

2026 May 7.
Patent

US20180263995A1.

Solvente y solubilidad

In Vitro:

DMSO : 33.33 mg/mL (95.94 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8786 mL

14.3930 mL

28.7861 mL

5 mM

0.5757 mL

2.8786 mL

5.7572 mL

10 mM

0.2879 mL

1.4393 mL

2.8786 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Picaud S, et al. PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains. Cancer Res. 2013 May 21. [Epub ahead of print] [Content Brief]

[2]. Fish PV, et al. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J Med Chem. 2012 Nov 26;55(22):9831-7. [Content Brief]

[3]. Cheng Z, et al. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res. 2013 Apr 1;19(7):1748-59. [Content Brief]

[4]. Kate E Lines, et al. Epigenetic modifiers reduce proliferation of human neuroendocrine tumour cell lines. Endocrine Abstracts (2013) 31 P149

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8786 mL	14.3930 mL	28.7861 mL	71.9652 mL
	5 mM	0.5757 mL	2.8786 mL	5.7572 mL	14.3930 mL
	10 mM	0.2879 mL	1.4393 mL	2.8786 mL	7.1965 mL
	15 mM	0.1919 mL	0.9595 mL	1.9191 mL	4.7977 mL
	20 mM	0.1439 mL	0.7197 mL	1.4393 mL	3.5983 mL
	25 mM	0.1151 mL	0.5757 mL	1.1514 mL	2.8786 mL
	30 mM	0.0960 mL	0.4798 mL	0.9595 mL	2.3988 mL
	40 mM	0.0720 mL	0.3598 mL	0.7197 mL	1.7991 mL
	50 mM	0.0576 mL	0.2879 mL	0.5757 mL	1.4393 mL
	60 mM	0.0480 mL	0.2399 mL	0.4798 mL	1.1994 mL
	80 mM	0.0360 mL	0.1799 mL	0.3598 mL	0.8996 mL

Keywords

PFI-1

4 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

PFI-1

Apoptosis Compound Library

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Reprogramming Compound Library

Chemical Probe Library

Anti-Blood Cancer Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) PFI-1

Ver todos los productos específicos de isoformas Epigenetic Reader Domain

Actividad biológica

Chemical Information

Publications (4)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

PFI-1

Apoptosis Compound Library

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Reprogramming Compound Library

Chemical Probe Library

Anti-Blood Cancer Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) PFI-1

Ver todos los productos específicos de isoformas Epigenetic Reader Domain

Actividad biológica

Chemical Information

Publications (4)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

PFI-1 Related Classifications

HY-16586 Related Classifications